Taiwan Liposome Company General Manager George Yeh: An Interview With PharmAsia News (Part 2 Of 2)
This article was originally published in PharmAsia News
Executive Summary
Taiwan Liposome Company General Manager George Yeh recently spoke with PharmAsia News about the drug delivery company's partnership strategy and its plans to expand beyond Southeast Asia. TLC, based in South San Francisco and Taipei, is engaged in research, development and commercialization of proprietary drug-delivery systems for improving the treatment of cancer, ophthalmic conditions and infectious diseases.
You may also be interested in...
Taiwan Liposome Company Nearing IPO After Round Of Financing
HONG KONG - A cash injection from a U.S. venture capital firm may help a Taiwanese developer of drug delivery systems better compete on a global scale as it moves towards an initial public offering
Taiwan Liposome Company Nearing IPO After Round Of Financing
HONG KONG - A cash injection from a U.S. venture capital firm may help a Taiwanese developer of drug delivery systems better compete on a global scale as it moves towards an initial public offering
Taiwan Government Supports Creating Solid Clinical Trial Environment - DIA Exclusive
BOSTON - Taiwan's Bureau of Pharmaceutical Affairs and Center for Drug Evaluation brought a large delegation to promote the country's clinical trial environment at the Drug Information Association's 44th annual meeting held this year in Boston. BPA Deputy-Director General Li-Ling Liu and CDE Executive Director Herng-Der Chern, spoke with PharmAsia News on the sidelines of the conference about the country's efforts to make Taiwan an attractive location for clinical development